



US 20210317476A1

(19) **United States**(12) **Patent Application Publication**
Pei et al.(10) **Pub. No.: US 2021/0317476 A1**(43) **Pub. Date: Oct. 14, 2021**(54) **FOWL ADENOVIRUS 9 (FADV-9) VECTOR
SYSTEM AND ASSOCIATED METHODS**(71) Applicant: **University of Guelph**, Guelph (CA)(72) Inventors: **Yanlong Pei**, Guelph (CA); **James
Ackford**, Whitby (CA); **Juan Carlos
Corredor**, Calgary (CA); **Peter J.
Krell**, Guelph (CA); **Eva Nagy**, Guelph
(CA)(21) Appl. No.: **17/244,079**(22) Filed: **Apr. 29, 2021****Related U.S. Application Data**(63) Continuation of application No. 15/743,459, filed on
Jan. 23, 2018, now abandoned, filed as application
No. PCT/CA2016/050811 on Jul. 11, 2016.(60) Provisional application No. 62/190,913, filed on Jul.
10, 2015.**Publication Classification**(51) **Int. Cl.**
C12N 15/86 (2006.01)(52) **U.S. Cl.**
CPC **C12N 15/86** (2013.01); **C12N 2710/10243**
(2013.01); **C12N 2830/00** (2013.01); **C12N**
2510/00 (2013.01); **C12N 2830/48** (2013.01)(57) **ABSTRACT**

Described are recombinant viral vectors obtained from fowl adenovirus 9 (FAdV-9) and associated methods. The recombinant FAdV-9 vectors may include one or more deletions at the left end and/or right end of the FAdV-9 genome. Optionally, the vectors include one or more exogenous nucleotide sequences, such as sequences encoding for a polypeptide of interest. The recombinant FAdV-9 vectors may be used as a dual delivery vector. Also described is the use of the vectors for generating an immunogenic response in a subject and/or for the prevention of disease.

Specification includes a Sequence Listing.